Atea Pharmaceuticals
AVIR
108 hedge funds and large institutions have $170M invested in Atea Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 45 increasing their positions, 30 reducing their positions, and 21 closing their positions.
73% more call options, than puts
Call options by funds: $292K | Put options by funds: $169K
50% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 30
1% less capital invested
Capital invested by funds: $171M → $170M (-$1.06M)
1.65% less ownership
Funds ownership: 68.17% → 66.52% (-1.7%)
9% less funds holding
Funds holding: 119 → 108 (-11)
48% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 21
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.79M |
| 2 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$2.01M |
| 3 |
Morgan Stanley
New York
|
+$1.67M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.44M |
| 5 |
Barclays
London,
United Kingdom
|
+$519K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.34M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.67M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$1.8M |
| 4 |
Vontobel Holding
Zurich,
Switzerland
|
-$1.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.25M |
AVIR Hedge Fund Activity: Q4 2023 in Review
108 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q4 2023, worth a combined $170M — down 0.62% from $171M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of AVIR and 11 opened new positions — a net loss of 10 holders — while 30 trimmed existing stakes and 45 added.
The largest buyer was BlackRock, adding an estimated $3.79M. The largest seller was Fidelity Investments, cutting an estimated $3.34M.
- 108 institutional investors held Atea Pharmaceuticals (AVIR) as of Q4 2023, down from 119 in Q3 2023.
- Funds reported $170M of Atea Pharmaceuticals stock for Q4 2023, down 0.62% quarter-over-quarter.
- 11 funds opened new Atea Pharmaceuticals positions in Q4 2023 and 21 closed out, a net change of -10 holders.
- The largest Atea Pharmaceuticals buyer in Q4 2023 was BlackRock, an estimated $3.79M added.
- The largest Atea Pharmaceuticals seller in Q4 2023 was Fidelity Investments, an estimated $3.34M sold.
Based on aggregated 13F filings for Q4 2023.